You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePentazocine
Accession NumberDB00652  (APRD01173)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionThe first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Structure
Thumb
Synonyms
Fortral
Pentazocin
Pentazocina
Pentazocine
Pentazocinum
External Identifiers
  • CS 350
  • NIH 7958
  • Win 20228
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Talwininjection, solution30 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.2010-10-12Not applicableUs
Talwininjection, solution30 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.2010-10-12Not applicableUs
Talwininjection, solution30 mg/mLintramuscular; intravenous; subcutaneousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Talwintablet50 mgoralSanofi Aventis Canada Inc1970-12-31Not applicableCanada
Talwin - Liq 30mg/mlliquid30 mgintramuscular; intravenous; subcutaneousSanofi Synthelabo Canada Inc1967-12-312001-08-10Canada
Talwin 30 mg/mlsolution30 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation2002-11-01Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FortalSanofi-Aventis
FortralSanofi-Aventis
FortwinTerapia
PangonL.B.S.
PentaginDaiichi Sankyo
SosegonSanofi-Aventis
StopainBeximco
Talwin PXSanofi-Aventis
Brand mixtures
NameLabellerIngredients
Pentazocine and NaloxoneActavis Pharma, Inc.
Pentazocine HCl and AcetaminophenRebel Distributors Corp
Pentazocine HCl and Naloxone HClSTAT Rx USA LLC
Pentazocine Hydrochloride and AcetaminophenGAVIS Pharmaceuticals, LLC
Pentazocine Hydrochloride and Naloxone HydrochlorideGAVIS Pharmaceuticals, LLC
Salts
Name/CASStructureProperties
Pentazocine Hydrochloride
ThumbNot applicableDBSALT001009
Pentazocine Lactate
ThumbNot applicableDBSALT001010
Categories
UNIIRP4A60D26L
CAS number359-83-1
WeightAverage: 285.4238
Monoisotopic: 285.209264491
Chemical FormulaC19H27NO
InChI KeyInChIKey=VOKSWYLNZZRQPF-GDIGMMSISA-N
InChI
InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1
IUPAC Name
(1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0²,⁷]trideca-2,4,6-trien-4-ol
SMILES
C[[email protected]]1[[email protected]]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 6,7-benzomorphans. These are opioid alkaloids based on the tricyclic 6,7-benzomorphan skeleton. Benzomorphans lack the C ring of morphine.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
Class6,7-benzomorphans
Sub ClassNot Available
Direct Parent6,7-benzomorphans
Alternative Parents
Substituents
  • 6,7-benzomorphan
  • Benzazocine
  • Tetralin
  • Aralkylamine
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the relief of moderate to severe pain.
PharmacodynamicsPentazocine is a potent analgesic which when administered orally in a 50 mg dose appears equivalent in analgesic effect to 60 mg (1 grain) of codeine. Onset of significant analgesia usually occurs between 15 and 30 minutes after oral administration, and duration of action is usually three hours or longer. Onset and duration of action and the degree of pain relief are related both to dose and the severity of pretreatment pain. Pentazocine weakly antagonizes the analgesic effects of morphine and meperidine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. Pentazocine has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.
Mechanism of actionThe preponderance of evidence suggests that pentazocine antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor.
Related Articles
AbsorptionWell absorbed from the gastro-intestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic

Route of eliminationNot Available
Half life2 to 3 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Pentazocine Action PathwayDrug actionSMP00686
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9931
Blood Brain Barrier+0.9769
Caco-2 permeable+0.7902
P-glycoprotein substrateSubstrate0.9014
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.6975
Renal organic cation transporterInhibitor0.6982
CYP450 2C9 substrateNon-substrate0.7947
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7819
CYP450 1A2 substrateInhibitor0.5886
CYP450 2C9 inhibitorNon-inhibitor0.8321
CYP450 2D6 inhibitorInhibitor0.8147
CYP450 2C19 inhibitorNon-inhibitor0.8585
CYP450 3A4 inhibitorNon-inhibitor0.8155
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.778
Ames testNon AMES toxic0.8231
CarcinogenicityNon-carcinogens0.9322
BiodegradationNot ready biodegradable0.9888
Rat acute toxicity2.4411 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6301
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Injection, solutionintramuscular; intravenous; subcutaneous30 mg/mL
Tabletoral50 mg
Liquidintramuscular; intravenous; subcutaneous30 mg
Solutionintramuscular; intravenous; subcutaneous30 mg
Prices
Unit descriptionCostUnit
Talwin 30 mg/ml vial14.78USD ml
Talwin 30 mg/ml ampul4.86USD ml
Talwin 30 mg/ml1.64USD ml
Talwin 50 mg Tablet0.47USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point146.3 °CPhysProp
logP4.64DAYLIGHT (1999)
pKa8.88SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.122 mg/mLALOGPS
logP4.44ALOGPS
logP3.89ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)7.59ChemAxon
pKa (Strongest Basic)12.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity89.8 m3·mol-1ChemAxon
Polarizability33.86 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN02AD01
AHFS Codes
  • 28:08.12
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (48.4 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Pentazocine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Pentazocine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with 7-Nitroindazole.
AcepromazineAcepromazine may increase the hypotensive activities of Pentazocine.
AcepromazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Pentazocine.
adipiplonThe risk or severity of adverse effects can be increased when Pentazocine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Alfaxalone.
AlfentanilPentazocine may decrease the analgesic activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Pentazocine.
AlimemazineAlimemazine may increase the hypotensive activities of Pentazocine.
AlphacetylmethadolPentazocine may decrease the analgesic activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Pentazocine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pentazocine.
AlvimopanThe risk or severity of adverse effects can be increased when Pentazocine is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amiloride.
AmisulprideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Pentazocine which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amobarbital.
AmoxapinePentazocine may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pentazocine.
AmperozideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Pentazocine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pentazocine.
AripiprazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Asenapine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pentazocine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pentazocine.
AzaperoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Azaperone.
AzelastinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pentazocine.
AzosemideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Pentazocine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Pentazocine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pentazocine.
BenzocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Pentazocine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benzyl alcohol.
BezitramidePentazocine may decrease the analgesic activities of Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pentazocine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
BrimonidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pentazocine.
BuprenorphineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pentazocine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pentazocine.
ButacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pentazocine.
Canrenoic acidThe risk or severity of adverse effects can be increased when Pentazocine is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pentazocine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Carbinoxamine.
CarfentanilPentazocine may decrease the analgesic activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Pentazocine.
CarisoprodolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pentazocine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chloroprocaine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Pentazocine.
ChlorphentermineChlorphentermine may increase the analgesic activities of Pentazocine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Pentazocine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pentazocine.
CitalopramPentazocine may increase the serotonergic activities of Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with clomethiazole.
ClomipraminePentazocine may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pentazocine.
ClonazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pentazocine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Pentazocine.
CocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cocaine.
CodeinePentazocine may decrease the analgesic activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pentazocine.
ConivaptanThe risk or severity of adverse effects can be increased when Pentazocine is combined with Conivaptan.
CyclizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pentazocine.
CyclothiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pentazocine.
DapoxetinePentazocine may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pentazocine.
deramciclaneThe risk or severity of adverse effects can be increased when Pentazocine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pentazocine.
DesmopressinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pentazocine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pentazocine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Pentazocine.
DextromoramidePentazocine may decrease the analgesic activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pentazocine.
DextropropoxyphenePentazocine may decrease the analgesic activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pentazocine.
DezocinePentazocine may decrease the analgesic activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Pentazocine.
DiazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Diazepam.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentazocine.
DifenoxinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Difenoxin.
DihydrocodeinePentazocine may decrease the analgesic activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pentazocine.
DihydroetorphinePentazocine may decrease the analgesic activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pentazocine.
DihydromorphinePentazocine may decrease the analgesic activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pentazocine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Diphenhydramine.
DiphenoxylatePentazocine may decrease the analgesic activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pentazocine.
DoramectinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
DoxylamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Doxylamine.
DPDPEPentazocine may decrease the analgesic activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Pentazocine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Pentazocine.
DrospirenoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pentazocine.
EcgonineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Pentazocine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Pentazocine is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Efonidipine.
EluxadolinePentazocine may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pentazocine.
EntacaponeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Entacapone.
EplerenoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Eplerenone.
EscitalopramPentazocine may increase the serotonergic activities of Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pentazocine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etacrynic acid.
EthanolPentazocine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Pentazocine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pentazocine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pentazocine.
EthosuximideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl loflazepate.
EthylmorphinePentazocine may decrease the analgesic activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pentazocine.
EtidocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pentazocine.
EtoperidonePentazocine may increase the serotonergic activities of Etoperidone.
EtorphinePentazocine may decrease the analgesic activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pentazocine.
EzogabineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fencamfamine.
FenfluraminePentazocine may increase the serotonergic activities of Fenfluramine.
FentanylPentazocine may decrease the analgesic activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pentazocine.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Pentazocine.
FexofenadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flunitrazepam.
FluoxetinePentazocine may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Pentazocine.
FluphenazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluticasone Propionate.
FluvoxaminePentazocine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Pentazocine.
FosphenytoinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Pentazocine is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pentazocine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Pentazocine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Pentazocine.
GuanfacineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pentazocine.
HalothaneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Halothane.
HeroinPentazocine may decrease the analgesic activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Pentazocine.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Pentazocine.
HexobarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Pentazocine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydrochlorothiazide.
HydrocodonePentazocine may decrease the analgesic activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pentazocine.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydroflumethiazide.
HydromorphonePentazocine may decrease the analgesic activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pentazocine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Pentazocine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
HydroxyzineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pentazocine.
IloperidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Imipramine.
IndalpinePentazocine may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Indapamide.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentazocine.
IsofluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Isoflurane.
IsosorbideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Isosorbide.
KetamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ketazolam.
KetobemidonePentazocine may decrease the analgesic activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pentazocine.
KW-3902The risk or severity of adverse effects can be increased when Pentazocine is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levodopa.
Levomethadyl AcetatePentazocine may decrease the analgesic activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pentazocine.
LevomilnacipranPentazocine may increase the serotonergic activities of Levomilnacipran.
LevorphanolPentazocine may decrease the analgesic activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pentazocine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Pentazocine.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Pentazocine.
LithiumThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lithium.
LofentanilPentazocine may decrease the analgesic activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Pentazocine.
LoratadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pentazocine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pentazocine.
Lu AA21004Pentazocine may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Pentazocine.
LurasidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pentazocine.
MeclizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Pentazocine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Pentazocine.
MepivacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pentazocine.
MersalylThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Pentazocine.
MesoridazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metaxalone.
MethadonePentazocine may decrease the analgesic activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Pentazocine.
Methadyl AcetatePentazocine may decrease the analgesic activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Pentazocine.
MethamphetamineMethamphetamine may increase the analgesic activities of Pentazocine.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pentazocine.
MethapyrileneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pentazocine.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Pentazocine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Pentazocine.
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Pentazocine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methylphenobarbital.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Pentazocine.
MetolazoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metolazone.
MetyrosinePentazocine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Midazolam.
MilnacipranPentazocine may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
MirtazapinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pentazocine.
MolindoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Pentazocine.
MorphinePentazocine may decrease the analgesic activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pentazocine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Pentazocine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
NabiloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nalbuphine.
NaloxegolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Naloxegol.
NaltrexoneThe therapeutic efficacy of Pentazocine can be decreased when used in combination with Naltrexone.
NitrazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nitrous oxide.
NormethadonePentazocine may decrease the analgesic activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Pentazocine.
NortriptylineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Pentazocine.
OlanzapinePentazocine may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pentazocine.
OlopatadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ondansetron.
OpiumPentazocine may decrease the analgesic activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Pentazocine.
OrphenadrinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pentazocine.
OsanetantThe risk or severity of adverse effects can be increased when Pentazocine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentazocine.
OxycodonePentazocine may decrease the analgesic activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pentazocine.
OxymorphonePentazocine may decrease the analgesic activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pentazocine.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pentazocine.
PaliperidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pentazocine.
ParaldehydePentazocine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Pentazocine.
ParoxetinePentazocine may increase the serotonergic activities of Paroxetine.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pentazocine.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pentazocine.
PerampanelThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Pentazocine.
PerphenazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perphenazine.
PethidinePentazocine may decrease the analgesic activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pentazocine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Pentazocine.
PhenytoinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pentazocine.
PipotiazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentazocine.
PiretanideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pomalidomide.
PotassiumThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium Citrate.
PramipexolePentazocine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pentazocine.
PrilocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Procaine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Pentazocine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pentazocine.
PromazinePromazine may increase the hypotensive activities of Pentazocine.
PromazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Pentazocine.
PromethazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pentazocine.
ProparacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Pentazocine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Pentazocine.
RamelteonThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ramelteon.
RamosetronPentazocine may increase the constipating activities of Ramosetron.
RemifentanilPentazocine may decrease the analgesic activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pentazocine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pentazocine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pentazocine.
RisperidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Risperidone.
RomifidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Romifidine.
RopinirolePentazocine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pentazocine.
RotigotinePentazocine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pentazocine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Pentazocine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pentazocine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Pentazocine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pentazocine.
SertindoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sertindole.
SertralinePentazocine may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Pentazocine.
SpironolactoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Pentazocine.
SufentanilPentazocine may decrease the analgesic activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pentazocine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pentazocine.
SuvorexantThe risk or severity of adverse effects can be increased when Pentazocine is combined with Suvorexant.
TapentadolPentazocine may decrease the analgesic activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pentazocine.
TasimelteonThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pentazocine.
TetrabenazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrodotoxin.
ThalidomidePentazocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pentazocine.
TheobromineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Pentazocine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Pentazocine.
ThioridazineThioridazine may increase the hypotensive activities of Pentazocine.
ThioridazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tiagabine.
TicrynafenThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Pentazocine.
TizanidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pentazocine.
TolvaptanThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Torasemide.
TramadolPentazocine may decrease the analgesic activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pentazocine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tranylcypromine.
TrazodonePentazocine may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Pentazocine.
TriamtereneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Pentazocine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Pentazocine.
TriflupromazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pentazocine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pentazocine.
TrimipramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pentazocine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pentazocine.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pentazocine.
UlaritideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Pentazocine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pentazocine.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Pentazocine.
VigabatrinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Vigabatrin.
VilazodonePentazocine may increase the serotonergic activities of Vilazodone.
VortioxetinePentazocine may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pentazocine.
XylazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ziconotide.
ZimelidinePentazocine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pentazocine.
ZolazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pentazocine.
ZonisamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Levine JD, Gordon NC: Synergism between the analgesic actions of morphine and pentazocine. Pain. 1988 Jun;33(3):369-72. [PubMed:3419842 ]
  2. Martin BR, Katzen JS, Woods JA, Tripathi HL, Harris LS, May EL: Stereoisomers of [3H]-N-allylnormetazocine bind to different sites in mouse brain. J Pharmacol Exp Ther. 1984 Dec;231(3):539-44. [PubMed:6094791 ]
  3. Kamei J, Iwamoto Y, Misawa M, Nagase H, Kasuya Y: Effects of diabetes on the antinociceptive effect of (+/-)pentazocine in mice. Res Commun Chem Pathol Pharmacol. 1994 Apr;84(1):105-10. [PubMed:8042002 ]
  4. Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41. [PubMed:8968334 ]
  5. Saha N, Datta H, Sharma PL: Effects of morphine, buprenorphine, pentazocine and nalorphine on acquisition and extinction of active avoidance responses in rats. Indian J Physiol Pharmacol. 1990 Jul;34(3):179-82. [PubMed:2286420 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Chien CC, Pasternak GW: (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol. 1995 Dec 27;294(1):303-8. [PubMed:8788445 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. Also regulates ion channels like the potassium channel and could modulate neurotransmitt...
Gene Name:
SIGMAR1
Uniprot ID:
Q99720
Molecular Weight:
25127.52 Da
References
  1. Chien CC, Pasternak GW: (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol. 1995 Dec 27;294(1):303-8. [PubMed:8788445 ]
  2. Colabufo NA, Contino M, Inglese C, Niso M, Perrone R, Roperto S, Roperto F: In vitro and ex vivo characterization of sigma-1 and sigma-2 receptors: agonists and antagonists in biological assays. Cent Nerv Syst Agents Med Chem. 2009 Sep;9(3):161-71. [PubMed:20021350 ]
  3. Dun Y, Thangaraju M, Prasad P, Ganapathy V, Smith SB: Prevention of excitotoxicity in primary retinal ganglion cells by (+)-pentazocine, a sigma receptor-1 specific ligand. Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4785-94. [PubMed:17898305 ]
  4. Mamolo MG, Zampieri D, Zanette C, Florio C, Collina S, Urbano M, Azzolina O, Vio L: Substituted benzylaminoalkylindoles with preference for the sigma2 binding site. Eur J Med Chem. 2008 Oct;43(10):2073-81. Epub 2007 Sep 26. [PubMed:18069094 ]
  5. Pal A, Hajipour AR, Fontanilla D, Ramachandran S, Chu UB, Mavlyutov T, Ruoho AE: Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe. Mol Pharmacol. 2007 Oct;72(4):921-33. Epub 2007 Jul 10. [PubMed:17622576 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23